On November 18, 2021, Ginkgo Bioworks was sued for violations of the federal securities laws in the United States District Court for the Northern District of California on behalf of investors who purchased the Company’s securities between May 11, 2021 and October 5, 2021.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.